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Global trends in vaccination coverage
Universal vaccination programmes have greatly 
reduced the burden of infectious diseases in both 
developing and developed countries.1–3 In the 1960s and 
1970s, these reductions led to optimism that a victory 
in the battle against infectious diseases could be within 
reach. Unfortunately, even though the beneﬁ ts of most 
childhood vaccinations are scientiﬁ cally unquestioned, 
vaccination coverage rates are far from 100% in 
many countries, and show substantial variation. Early 
detection of trends and an improved understanding of 
underlying mechanisms are paramount to be able to 
improve vaccination policies.
In The Lancet Global Health, Alexandre de Figueiredo 
and colleagues4  take a step in this direction with their 
time-series analysis of trends in vaccine coverage and 
a suite of socioeconomic and demographic factors 
across 190 countries over 30 years. Th e main aim was 
to gauge where and when vaccination coverage might 
fall below levels that are safe for prevention of epidemic 
transmission, and to correlate such decreases with 
underlying socioeconomic and demographic factors.
The investigators used WHO–UNICEF coverage 
estimates of three doses of diphtheria, tetanus, and 
pertussis (DTP3) vaccination and obtained data from 
Gapminder. By use of a statistical framework based on 
Gaussian process regression and a newly developed 
vaccine performance index, which forecasts that 
vaccination coverage will be at a safe level (90%) in 
the near future, the analyses yield some interesting 
results next to the basic fact that worldwide coverage 
has increased. For instance, gross domestic product 
(GDP) and government health spending correlate 
most strongly with vaccination coverage in Eastern 
Mediterranean countries between 1980 and 2010, 
whereas primary school completion correlates most 
strongly with vaccination coverage in Africa (more 
so than does GDP). The analyses also provide a list 
of countries with high to low vaccine performance 
indices, showing that many of the countries at the low 
end of the list are in sub-Saharan Africa, the Indian 
subcontinent, and southeast Asia. From a global 
public health perspective, the list provides an objective 
measure that can be used to prioritise countries or 
regions where eﬀ orts to increase vaccination coverage 
are expected to be most eﬃ  cient.
Notably, although vaccination coverage correlates well 
with GDP and schooling in many regions of the world, 
this is not the case any more in Europe and, to a lesser 
extent, North America. Here, no socioeconomic factors 
correlated with high coverage, and one argument is 
that once the basic necessities of life are available, other 
factors such as social attitudes to vaccination might 
become more important.5,6 Because of the focus on 
socioeconomic factors, de Figueiredo and colleagues’ 
ﬁ ndings cannot add much more than speculation to this 
argument, and it will be interesting to see the outcomes 
when the set of variables is extended to encompass 
social indicators that might shape vaccine hesitancy.7
With a focus on global immunisation patterns and the 
relation with socioeconomic factors, the investigators 
have painted a picture with broad brushes, one that 
cannot hope to unravel patterns that are important 
in speciﬁ c regions or countries and for particular 
diseases. Examples are the diﬃ  culties encountered in 
the push towards eradication of polio in Afghanistan 
and Pakistan driven by war and extreme ideologies,8 
the struggle to achieve elimination of measles in 
Europe given vaccine refusal in clustered religious and 
anthroposophical groups, and the perceived lack of 
safety of the human papillomavirus vaccine fuelled by 
adverse events after vaccination.9 These examples show 
that a full understanding of local coverage patterns 
requires data and analyses at the local level. 
Technically, the vaccine performance index might 
have to be developed further. The index provides an 
aggregate measure that takes both vaccination coverage 
and changes in coverage into account. One could argue 
that in its current form the vaccine performance index 
punishes countries with systematically high but volatile 
vaccination coverage (eg, Norway) quite strongly. In 
fact, low vaccine performance indices in these countries 
might be due to reporting bias or small sample sizes (in 
cases when a national registry is not available). Indeed, 
in developing countries, precise ﬁ gures for vaccination 
coverage are often not available, and estimation of 
vaccination coverage is not always straightforward.10,11 
Future developments will probably have to incorporate 
the uncertainty in vaccination coverage estimates 
to prevent artiﬁ cial increases in the precision of the 
correlations. 
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Overall, de Figueiredo and colleagues have provided 
a laudable analysis of the link between vaccination 
coverage rates and demographic and socioeconomic 
factors at the global scale. In addition to providing 
an overview of trends and potential explanations, an 
important merit of the study is that it forces us to think 
about the factors that determine vaccination coverage 
now and in the future.
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